Where does RGNT stock trade?

Regentis Biomaterials Ltd. (RGNT) is listed on AMEX.

What sector and industry is RGNT in?

Regentis Biomaterials Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Regentis Biomaterials Ltd. go public?

Regentis Biomaterials Ltd. (RGNT) completed its IPO in 2025.

What companies are similar to RGNT?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RGNT side-by-side with any of them on Quantisnow.

How can I track RGNT on Quantisnow?

Quantisnow aggregates Regentis Biomaterials Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNT to receive live email and push alerts on every new disclosure.

RGNT

AMEX

Regentis Biomaterials Ltd.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2025

$1.72-0.73 (-29.86%)

News25/Ratings0

Price$1.72-0.24 (-12.50%)

01:30 PM05:00 PM

News · 26 weeks37+500%

2025-12-142026-06-07

Mix1890d

Insider9(50%)
SEC Filings6(33%)
Market3(17%)

Latest news

25 items

1dSEC
Amendment: SEC Form F-1/A filed by Regentis Biomaterials Ltd.
F-1/A - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
2dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
2dNEWS
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European UnionRegentis is growing its network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinCGelrinC's 10-minute procedure offers a safe and effective alternative to traditional microfracture and complex cell-based therapies addressing a $3 billion U.S. market HERZLIYA, ISRAEL / ACCESS Newswire / June 8, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair soluti
5dSEC
Amendment: SEC Form 6-K/A filed by Regentis Biomaterials Ltd.
6-K/A - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
11dSEC
SEC Form FWP filed by Regentis Biomaterials Ltd.
FWP - REGENTIS BIOMATERIALS LTD. (0001912966) (Subject)
12dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
39dSEC
SEC Form F-1 filed by Regentis Biomaterials Ltd.
F-1 - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
55dNEWS
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoptionRenowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellence networkStrengthens surgeon engagement and expands Regentis' European commercialization infrastructureHERZLIYA, IL / ACCESS Newswire / April 16, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced a collaboration with Humanitas Research Hospital in Milan, Italy, one of Europe's leading academic medical centers in orthopedics and sports medicine. This collaboration is currently
71dINSIDER
SEC Form 3 filed by new insider Reske Galit
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
83dINSIDER
SEC Form 3 filed by new insider Geller Ehud
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
83dINSIDER
SEC Form 3 filed by new insider Valentine Keith
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
83dINSIDER
SEC Form 3 filed by new insider Alpert Susan Phd Md
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
83dINSIDER
SEC Form 3 filed by new insider Dykan Jeff
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
83dINSIDER
SEC Form 3 filed by new insider Cohen-Arazi Efraim
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
83dINSIDER
SEC Form 3 filed by new insider Gordashnikov Arie
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
83dINSIDER
SEC Form 3 filed by new insider Gon Ori
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
83dINSIDER
SEC Form 3 filed by new insider Ben-Elazar Pini
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
85dNEWS
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this yearProprietary process is already patented in several countries and is pending in the U.S.HERZLIYA, IL / ACCESS Newswire / March 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced it has developed a new manufacturing process for its lead product, GelrinC®, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. The proprietary new process does not require the use o
102dSEC
Amendment: SEC Form 20-F/A filed by Regentis Biomaterials Ltd.
20-F/A - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
105dSEC
SEC Form 20-F filed by Regentis Biomaterials Ltd.
20-F - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
105dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
105dNEWS
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
$7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinCAlready approved in Europe, GelrinC is expected to be rolled out in clinics across the continent in 2026GelrinC is positioned to be the first ready-to-use, off-the-shelf product in the U.S. for knee cartilage repairHERZLIYA, IL / ACCESS Newswire / February 24, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company"), a regenerative medicine company focused on innovative tissue repair solutions, today reported financial results for the year ended December 31, 2025 and provided an update on corporate and clinical developments."2025 w
111dNEWS
Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair
Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisitionHERZLIYA, ISRAEL / ACCESS Newswire / February 19, 2026 / Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the appointment of Dr. Galit Reske, PhD, as Chief Medical Officer (CMO). Dr. Reske brings extensive experience in clinical development, regulatory strategy, and global clinical operations across the United States, Europe, and Israel, with a particular focus on cartilage repair an
112dSEC
SEC Form SCHEDULE 13G filed by Regentis Biomaterials Ltd.
SCHEDULE 13G - REGENTIS BIOMATERIALS LTD. (0001912966) (Subject)
113dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)

RGNT FAQ

5 questions

Where does RGNT stock trade?
Regentis Biomaterials Ltd. (RGNT) is listed on AMEX.
What sector and industry is RGNT in?
Regentis Biomaterials Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Regentis Biomaterials Ltd. go public?
Regentis Biomaterials Ltd. (RGNT) completed its IPO in 2025.
What companies are similar to RGNT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RGNT side-by-side with any of them on Quantisnow.
How can I track RGNT on Quantisnow?
Quantisnow aggregates Regentis Biomaterials Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNT to receive live email and push alerts on every new disclosure.